KPV vs TB-500: Comparing Two Post-Category-2 Peptides
What KPV and TB-500 actually are
KPV is a three-amino-acid peptide (Lys-Pro-Val) that corresponds to the C-terminal end of alpha-melanocyte-stimulating hormone (alpha-MSH). Its conformational and receptor-binding behavior has been studied since at least 2001 (Conformational analysis of Ac-Lys-Pro-Val-NH2, 2001; MC1 receptor binding motif, 2006). It is not itself alpha-MSH and does not carry alpha-MSH's pigmentation or appetite effects in the studies available; the interest in KPV centers on anti-inflammatory and antimicrobial activity that appears independent of classic melanocortin receptor signaling in some models (dissection of anti-inflammatory core vs C-terminal effects, 2003).
TB-500 is commonly described as a synthetic peptide related to thymosin beta-4, marketed in research and compounding circles for tissue repair and recovery claims. This HealthRX.com cluster's verified source list is built around KPV and alpha-MSH literature; it does not include PMIDs specific to TB-500's mechanism or trial evidence. Any claim about TB-500's biological effects should be treated as unverified on this page until sourced separately, and readers weighing TB-500 for a specific use should ask a clinician to review primary evidence directly rather than relying on marketing summaries.
Are they regulated the same way right now?
The regulatory story is genuinely parallel, and that parallel is the reason this comparison exists. Both KPV and TB-500 were nominated for FDA's Category 2 list, a list the agency uses to flag bulk drug substances it believes present significant safety risks when compounded. Both nominations were later withdrawn by the nominators, which means neither peptide currently sits in FDA Category 2 (per the FDA's Category 2 bulk substances page, content current as of 04/22/2026) (FDA Category 2 bulk substances).
Withdrawal from Category 2 is not the same as approval, and it is not the same as being placed on the 503A bulks list, which is the list that actually governs what a compounding pharmacy may legally use (503A bulk drug substances framework). As of September 2026, neither KPV nor TB-500 is on the 503A list, and neither has FDA approval as a drug product.
On July 23-24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted 8 yes, 6 no, 1 abstain to recommend adding KPV to the 503A bulks list (PCAC July 23-24, 2026 meeting). The same meeting reportedly produced an identical 8-6-1 vote for TB-500, though this page relies on the same meeting record for that figure and readers should confirm the specific substance-by-substance vote breakdown against the official PCAC minutes rather than assume every peptide discussed that day received the same tally. A PCAC recommendation is advisory. It does not add anything to the 503A list on its own; HHS and FDA still have to act, and as of this writing neither peptide has been added.
Why the vote split matters more than the yes count
An 8-6-1 vote is not a consensus. Six committee members voted no and one abstained, which means a substantial minority of the FDA's own advisory panel was not convinced the safety and compounding-need case was settled. Readers who see "PCAC recommended it" repeated as if it settles the question are getting an incomplete picture. The honest framing is: a slim majority of an advisory committee thinks the substance is a reasonable 503A candidate, the agency has not yet decided, and the substance is not currently legal to compound under an established federal framework.
How does the evidence depth compare?
This is where KPV and TB-500 diverge for HealthRX.com's purposes. KPV has a two-decade line of published research, almost entirely cell-culture and animal-model work rather than human clinical trials. Highlights include anti-inflammatory activity in colitis models via the PepT1 transporter (PepT1-mediated KPV uptake reduces intestinal inflammation, 2008; PepT1 and colitis-associated cancer, 2016), corneal wound healing via nitric oxide pathways (alpha-MSH(11-13) and corneal epithelial healing, 2006), antimicrobial and antifungal activity against organisms including Candida albicans ((CKPV)2 anti-fungal effects in vaginitis model, 2013; antimicrobial melanocortin peptides, 2008), and a broad review of anti-inflammatory melanocortin peptides as candidate drugs for immune-mediated inflammatory disease (alpha-MSH related peptides as anti-inflammatory drugs, endocrine review, 2008). None of this constitutes a completed human efficacy trial for any specific condition, and readers should not read cell-culture or mouse-model results as evidence of what KPV does in a person.
This HealthRX.com cluster does not carry an equivalent PMID list for TB-500, which is a meaningful gap for anyone trying to compare the two peptides on evidence rather than regulatory status alone. Treat a claim that TB-500 has "similar research support" to KPV as unverified until a comparable sourced review exists.
A framework for reading peptide regulatory news
| Signal | What it actually means | What it does not mean |
|---|---|---|
| Nomination withdrawn from Category 2 | The substance is no longer flagged by FDA as presenting significant compounding safety risk under that specific nomination | The substance is approved, safe, or legal to compound |
| PCAC recommends adding to 503A | A majority of an advisory committee thinks the substance meets criteria for the bulks list | The substance is on the list; HHS/FDA still must act |
| Vote margin (e.g. 8-6-1) | Degree of expert consensus or disagreement | A close vote does not carry less legal weight than a unanimous one, but it signals unresolved safety or evidence questions worth asking a clinician about |
| Substance is not on 503A list | Compounding pharmacies do not have a clear federal pathway to use it | It says nothing about whether animal or cell-culture research is promising |
| Human trial evidence exists | Effects have been tested in people, with defined dosing and endpoints | It does not mean the trial supports the specific use a seller is marketing |
Use this table as a checklist before treating any peptide headline as a green light. For KPV specifically, every row above resolves to "not yet approved, not yet listed, evidence is preclinical."
What this means for someone considering either peptide
If a clinic or supplier tells you KPV or TB-500 is "FDA cleared" or "legal now" because of the Category 2 withdrawal or the PCAC vote, that is not an accurate reading of the regulatory record as of September 2026. If you are looking at KPV for a specific condition, the KPV pillar page and condition-specific pages on KPV for IBD and ulcerative colitis and KPV for eczema and psoriasis walk through the preclinical evidence in more depth, along with how KPV compares to established options on the KPV vs topical steroid page. Systemic use and dosing considerations are covered separately on the systemic KPV and KPV dosing pages.
Evidence boundary
Established: KPV's Category 2 nomination was withdrawn; KPV is not on the 503A bulks list; KPV is not FDA-approved; the PCAC voted 8-6-1 in July 2026 to recommend it for 503A, and that recommendation has not yet been acted on by FDA or HHS. KPV has meaningful preclinical evidence for anti-inflammatory and antimicrobial activity in cell and animal models.
Plausible but unproven: that KPV's preclinical anti-inflammatory mechanisms translate into clinically meaningful human benefit for any specific condition; that TB-500 shares a comparable regulatory or evidence trajectory beyond the shared vote and withdrawal pattern described here.
Not established: any human efficacy data for KPV in a defined clinical population from randomized trials; a comparable independently sourced evidence review for TB-500 within this cluster; any timeline for whether or when FDA will act on the PCAC recommendation for either substance.
If you are weighing either peptide for a specific health condition, that decision involves contraindications, drug interactions, and monitoring needs that depend on your individual history. Talk to a licensed clinician who can review your records, and treat any urgent symptom (severe abdominal pain, signs of infection, unexplained bleeding) as a reason to seek care rather than wait on a peptide protocol.